Avanir soars after Nuedexta approval

Avanir Pharmaceuticals Inc. (NASDAQ:AVNR) jumped $2.38 (98%) to $4.80 on Monday after FDA approved Nuedexta dextromethorphan/quinidine late Friday to treat pseudobulbar affect (PBA). The company submi...